212 related articles for article (PubMed ID: 30654465)
21. Common antibody dependent cell mediated cytotoxicity (ADCC) antibody epitopes of HIV-1 CRF01_AE Env and Gag in early HIV-1 infected individuals.
Sangjan S; Ampol S; Tabprasit S; Horthongkham N; Chuenchitra T; Ekpo P; Kantakamalakul W
Asian Pac J Allergy Immunol; 2019 Mar; 37(1):43-50. PubMed ID: 29602284
[TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
23. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
24. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.
Ampol S; Pattanapanyasat K; Sutthent R; Permpikul P; Kantakamalakul W
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1250-8. PubMed ID: 22288892
[TBL] [Abstract][Full Text] [Related]
26. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
27. Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells.
Mengistu M; Ray K; Lewis GK; DeVico AL
PLoS Pathog; 2015 Mar; 11(3):e1004772. PubMed ID: 25807494
[TBL] [Abstract][Full Text] [Related]
28. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
Qi Y; Jo S; Im W
Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
[TBL] [Abstract][Full Text] [Related]
29. Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies.
Flemming J; Wiesen L; Herschhorn A
AIDS Res Hum Retroviruses; 2018 Sep; 34(9):794-803. PubMed ID: 29905080
[TBL] [Abstract][Full Text] [Related]
30. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
[TBL] [Abstract][Full Text] [Related]
31. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.
Mayr LM; Decoville T; Schmidt S; Laumond G; Klingler J; Ducloy C; Bahram S; Zolla-Pazner S; Moog C
Sci Rep; 2017 Oct; 7(1):12655. PubMed ID: 28978939
[TBL] [Abstract][Full Text] [Related]
32. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
33. GP120: target for neutralizing HIV-1 antibodies.
Pantophlet R; Burton DR
Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
[TBL] [Abstract][Full Text] [Related]
34. Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.
Pollara J; Jones DI; Huffman T; Edwards RW; Dennis M; Li SH; Jha S; Goodman D; Kumar A; LaBranche CC; Montefiori DC; Fouda GG; Hope TJ; Tomaras GD; Staats HF; Ferrari G; Permar SR
J Virol; 2019 May; 93(10):. PubMed ID: 30842326
[TBL] [Abstract][Full Text] [Related]
35. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.
Guzzo C; Zhang P; Liu Q; Kwon AL; Uddin F; Wells AI; Schmeisser H; Cimbro R; Huang J; Doria-Rose N; Schmidt SD; Dolan MA; Connors M; Mascola JR; Lusso P
mBio; 2018 Dec; 9(6):. PubMed ID: 30538178
[TBL] [Abstract][Full Text] [Related]
36. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.
Spurrier B; Sampson JM; Totrov M; Li H; O'Neal T; Williams C; Robinson J; Gorny MK; Zolla-Pazner S; Kong XP
Structure; 2011 May; 19(5):691-9. PubMed ID: 21565703
[TBL] [Abstract][Full Text] [Related]
37. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.
Pietzsch J; Scheid JF; Mouquet H; Klein F; Seaman MS; Jankovic M; Corti D; Lanzavecchia A; Nussenzweig MC
J Exp Med; 2010 Aug; 207(9):1995-2002. PubMed ID: 20679402
[TBL] [Abstract][Full Text] [Related]
38. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].
Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S
Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660
[TBL] [Abstract][Full Text] [Related]
39. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
40. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
